Current Report Filing (8-k)
July 27 2022 - 04:34PM
Edgar (US Regulatory)
false000074859200007485922022-07-212022-07-21
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): July 21, 2022
Brooklyn ImmunoTherapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
001-11460
|
31-1103425
|
|
(State or
Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
10355 Science
Center Drive, Suite 150
|
|
|
|
San Diego,
California
|
|
92121
|
|
(Address of
Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s telephone number, including area code: (212) 582-1199
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each
class
|
|
Trading
symbol
|
|
Name of each
exchange on which registered
|
Common Stock, par value $0.005 per share
|
|
BTX
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or
Rule 12b-2 of the Securities Exchange Act of 1934:
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
|
Item 5.02 |
Departure of
Directors or Certain Officers; Election of Directors; Appointment
of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
On July 21, 2022, Dr. Kevin D’Amour, Chief Scientific Officer of
Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the
“Company”),
delivered his notice of resignation. The Company and Dr. D’Amour
have not yet determined the effective date of Dr. D’Amour’s
resignation.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, hereunto duly authorized.
|
|
Brooklyn
ImmunoTherapeutics, Inc.
|
|
|
|
|
Dated: July 27, 2022
|
By:
|
/s/ Dr. Matt Angel
|
|
|
|
Interim Chief Executive Officer and
President
|
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Feb 2023 to Mar 2023
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2022 to Mar 2023
